|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000103855 |
Summary for CD276 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000103855 | Gene symbol | CD276 |
| Gene name | CD276 molecule | |
| HGNC | 19137 | |
| Entrez ID | 80381 | |
| Gene type | protein_coding | |
| Synonyms | CD276|B7-H3|B7H3|B7RP-2 | |
| UniProtAcc | Q5ZPR3 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000103855 | CD276 | DB15635 | Omburtamab | BiotechDrug |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for CD276 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CD276 | 5.75e+03 | 1.02e+00 | 1.49e-01 | 6.82e+00 | 9.25e-12 | 1.70e-10 | STAD |
| CD276 | 8.43e+03 | 1.21e+00 | 3.07e-01 | 3.94e+00 | 8.22e-05 | 8.58e-04 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CD276 | 7.25e+03 | 1.22e+00 | 1.69e-01 | 7.20e+00 | 6.22e-13 | 5.95e-12 | LUSC |
| CD276 | 5.35e+03 | 1.03e+00 | 2.32e-01 | 4.46e+00 | 8.24e-06 | 1.84e-04 | BLCA |
| CD276 | 3.08e+03 | 1.24e+00 | 1.51e-01 | 8.17e+00 | 3.11e-16 | 3.54e-15 | COAD |
| CD276 | 3.40e+03 | 1.12e+00 | 2.84e-01 | 3.96e+00 | 7.58e-05 | 3.77e-04 | READ |
Top |
Sex-biased somatic mutation for CD276 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for CD276 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUSC | cg04289575 | chr15:73682835 | CGI:chr15:73684218-73684914 | promoter | 6.62e-01 | 8.25e-01 | -4.16e+00 | 3.19e-05 | 5.26e-04 | -1.63e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
Top |
Exon skipping events with PSI in TCGA for CD276 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for CD276 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for CD276 |
| TFs related to CD276. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CD276 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for CD276 |
| RBPs related to ES in CD276. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| UVM | STAR-PAP | exon_skip_123388 | 1.68e+01 | 1.00e+00 | 1.61e+01 | 7.27e-05 | Male-biased |
| THYM | ENOX1 | exon_skip_123404 | 9.70e+00 | 9.93e-01 | 9.30e+00 | 4.09e-03 | Male-biased |
| LIHC | ENOX1 | exon_skip_123404 | 9.73e+00 | 9.92e-01 | 9.26e+00 | 5.28e-03 | Male-biased |
| READ | STAR-PAP | exon_skip_123388 | 1.54e+01 | 5.66e-05 | 1.62e+01 | 1.00e+00 | Female-biased |
| MESO | STAR-PAP | exon_skip_123388 | 1.64e+01 | 9.98e-01 | 1.59e+01 | 2.34e-03 | Male-biased |
| GBM | STAR-PAP | exon_skip_123388 | 1.56e+01 | 6.68e-04 | 1.62e+01 | 9.99e-01 | Female-biased |
| KICH | STAR-PAP | exon_skip_123388 | 1.64e+01 | 1.00e+00 | 1.57e+01 | 4.71e-04 | Male-biased |
| SARC | STAR-PAP | exon_skip_123388 | 1.56e+01 | 5.19e-04 | 1.63e+01 | 9.99e-01 | Female-biased |
| CD276 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs16971220 | chr15:79657374:G:C | - | 0.0972004151359881 | 0.00950221059808241 | KIRC | Female-baised eQTL |
| rs16971198 | chr15:79642497:G:A | - | 0.0964576880023029 | 0.0107557013343572 | KIRC | Female-baised eQTL |
| rs16954053 | chr15:79663270:A:G | - | 0.0964576880023029 | 0.0107557013343572 | KIRC | Female-baised eQTL |
| rs151121478 | chr15:79651926:A:T | - | 0.0961855339831019 | 0.011378652831493 | KIRC | Female-baised eQTL |
| rs28459521 | chr15:79651187:T:G | - | 0.0786380340978563 | 0.0265262205008022 | KIRC | Female-baised eQTL |
| rs11635686 | chr15:73356739:C:T | - | 0.100039327392249 | 0.0238181734095375 | LUAD | Female-baised eQTL |
| rs28375532 | chr15:70226907:T:A | - | 0.07659591810146 | 0.0241386994084285 | LUAD | Female-baised eQTL |
| rs11636411 | chr15:73358861:T:C | - | 0.0988852305250644 | 0.0270461037588365 | LUAD | Female-baised eQTL |
| rs11636462 | chr15:73359039:T:G | - | 0.0988852305250644 | 0.0270461037588365 | LUAD | Female-baised eQTL |
| rs78680002 | chr15:73362501:G:A | - | 0.0988852305250644 | 0.0270461037588365 | LUAD | Female-baised eQTL |
| rs17689213 | chr15:70227738:G:A | - | 0.0717586910554889 | 0.0285818350019463 | LUAD | Female-baised eQTL |
| rs28375958 | chr15:70241671:G:A | - | 0.0752422892256122 | 0.0286170986563121 | LUAD | Female-baised eQTL |
| rs78152326 | chr15:73362895:C:A | - | 0.0971101957060706 | 0.0299025464993101 | LUAD | Female-baised eQTL |
| rs28633573 | chr15:70228547:G:A | - | 0.0745521068162009 | 0.032351701176383 | LUAD | Female-baised eQTL |
| rs919863 | chr15:70229241:C:A | - | 0.0745521068162009 | 0.032351701176383 | LUAD | Female-baised eQTL |
| rs28615702 | chr15:70229667:G:A | - | 0.0745521068162009 | 0.032351701176383 | LUAD | Female-baised eQTL |
| rs17767449 | chr15:70229966:T:C | - | 0.0745521068162009 | 0.032351701176383 | LUAD | Female-baised eQTL |
| rs28375952 | chr15:70230137:T:C | - | 0.0742778794653041 | 0.0337844648967197 | LUAD | Female-baised eQTL |
| rs11632433 | chr15:73174731:T:G | - | 0.0916981847944875 | 0.0342754628009678 | LUAD | Female-baised eQTL |
| rs34326722 | chr15:73200768:C:T | - | 0.0894331103131291 | 0.0374974552315923 | LUAD | Female-baised eQTL |
| rs2415083 | chr15:70231704:G:A | - | 0.0712961622358056 | 0.0388951406320074 | LUAD | Female-baised eQTL |
| rs28494039 | chr15:70225706:G:A | - | 0.0730279028907718 | 0.0427871619339232 | LUAD | Female-baised eQTL |
| rs925114 | chr15:79413177:A:G | - | 0.0696383323326672 | 0.0370056248365955 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs8025245 | chr15:80319446:T:C | - | 0.113657153971061 | 0.0268247685352895 | READ | Male-baised eQTL |
| rs2034248 | chr15:80319964:T:A | - | 0.110669933368813 | 0.0425372158956848 | READ | Male-baised eQTL |
| rs80343857 | chr15:74458605:T:C | - | 0.0489918271455149 | 0.0446459714688088 | LIHC | Male-baised eQTL |
| rs12442548 | chr15:74472450:A:G | - | 0.0489918271455149 | 0.0446459714688088 | LIHC | Male-baised eQTL |
| rs11635284 | chr15:64021565:A:G | - | -0.0555215159710926 | 0.0477522995214247 | KIRC | Male-baised eQTL |
| rs67974636 | chr15:67853647:T:G | - | 0.110737240522461 | 0.00267019968934857 | LUAD | Male-baised eQTL |
| rs35276980 | chr15:75599382:C:T | - | 0.0833744385174287 | 0.0170780630696916 | COAD | Male-baised eQTL |
| rs4776273 | chr15:63982925:C:T | - | 0.038848530080165 | 0.0210482265088268 | COAD | Male-baised eQTL |
| rs76107647 | chr15:75534846:G:A | - | 0.0810215558294244 | 0.0233312004636816 | COAD | Male-baised eQTL |
| rs140491687 | chr15:75325326:T:C | - | 0.0801494527546817 | 0.0310726914953979 | COAD | Male-baised eQTL |
| rs4776274 | chr15:63982952:T:C | - | 0.0369968424241729 | 0.0358543391358297 | COAD | Male-baised eQTL |
| rs8040233 | chr15:63987635:C:T | - | -0.0351178025990766 | 0.0491895812245156 | COAD | Male-baised eQTL |
| rs12148278 | chr15:63987887:T:C | - | -0.035096360757443 | 0.0493943009566877 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of CD276 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000103855 | CD276 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| ENSG00000103855 | CD276 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| ENSG00000103855 | CD276 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| ENSG00000103855 | CD276 | C2239176 | Liver carcinoma | 1 | CTD_human |
